<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0036">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Valencia</surname>
    <given-names>I.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Peiro</surname>
    <given-names>C.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Lorenzo</surname>
    <given-names>O.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Sanchez-Ferrer</surname>
    <given-names>C. F.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Eckel</surname>
    <given-names>J.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>Romacho</surname>
    <given-names>T.</given-names>
   </name>
  </person-group> (
  <year>2020</year>). 
  <article-title>DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications?</article-title>
  <source>
   <italic toggle="yes">Frontiers in Pharmacology</italic>
  </source>, , 
  <fpage>1161</fpage>
  <pub-id pub-id-type="doi">10.3389/fphar.2020.01161</pub-id>
  <pub-id pub-id-type="pmid">32848769</pub-id>
 </mixed-citation>
</ref>
